Search | Clinical Trials Finder

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: NASH
Interventions: EDP 305; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Congenital Heart Disease
Interventions: Treprostinil, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatic Insufficiency
Interventions: Mavorixafor; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Montclair, California • Rialto, California • Orlando, Florida + 1 more

Conditions: Diabete Type 2, Obesity
Interventions: HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Renal Insufficiency, Kidney Diseases
Interventions: INCB054707; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Tustin, California • Orlando, Florida • San Antonio, Texas

Conditions: HEPATITIS C (HCV)
Interventions: PF-868554; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida

Conditions: Hepatitis B Virus
Interventions: Cemiplimab; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts

Conditions: Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions: venipuncture, Questionnaires, Additional Sample Collections; Other · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years and older
Enrollment: 120,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Carcinoma, Hepatocellular
Interventions: Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • Clleveland, Ohio + 1 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more

Conditions: Alpha-1 Anti-trypsin Deficiency
Interventions: Not listed
Lead sponsor: Coram Clinical Trials; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Centennial, Colorado

Conditions: Chronic Hepatitis C
Interventions: GS-5816; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Impairment
Interventions: Divarasib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 4
States / cities: Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more

Conditions: Hepatitis C, Alcohol Use Disorder
Interventions: Neuropsychological assessment, Neuroimaging; Diagnostic Test · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Fort Myers, Florida • Detroit, Michigan • Portland, Oregon + 1 more

Conditions: Moderate Hepatic Impairment
Interventions: Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Liver Transplantation
Interventions: mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more

Conditions: Impaired Hepatic Function, Healthy
Interventions: ALXN2050; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Liver Disease
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Normal Hepatic Function, Impaired Hepatic Function
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Lakewood, Colorado • DeLand, Florida • Miami, Florida + 2 more

Conditions: COVID-19
Interventions: PF-07817883; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Anaheim, California • Garden Grove, California • Montclair, California + 2 more

Conditions: Multiple Myeloma
Interventions: Not listed
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: No City Provided, New Jersey

Conditions: Hepatic Failure, Liver Failure
Interventions: 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose; Drug
Lead sponsor: Cardiox Corporation; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Acute Effects of Inhaled Treprostinil in Fontan Patients

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

Study of ALXN2050 in Participants With Hepatic Impairment

The Physiology of Fatigue in Patients With Chronic Liver Disease

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Cardiox Liver Function Test Pivotal Trial